Results 121 to 130 of about 2,243,647 (283)

Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer

Tumor Biology, 2016
Pancreatic ductal adenocarcinoma (PDAC) ranks fourth among cancer-related deaths. The nucleoside analog gemcitabine has been the cornerstone of adjuvant chemotherapy in PDAC for decades. However, gemcitabine resistance develops within weeks of chemotherapy initiation, which might be intrinsic to cancer cells and influenced by tumor microenvironment ...
Yang, Liu, Fan, Li, Feng, Gao, Lingxi, Xing, Peng, Qin, Xingxin, Liang, Jiajie, Zhang, Xiaohui, Qiao, Lizhou, Lin, Qian, Zhao, Lianfang, Du   +10 more
openaire   +2 more sources

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma

, 2018
Gemcitabine resistance is currently the main problem of chemotherapy for advanced pancreatic cancer patients. The resistance is thought to be caused by altered drug metabolism or reduced apoptosis of cancer cells.
Qiang Huang, Feng Shao, Mei Huang, Futao Meng   +3 more
core   +1 more source

lncRNA GAS5 Reverses EMT and Tumor Stem Cell-Mediated Gemcitabine Resistance and Metastasis by Targeting miR-221/SOCS3 in Pancreatic Cancer

Molecular Therapy: Nucleic Acids, 2018
Dysregulated long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) mediating chemotherapeutic drug effects and metastasis in pancreatic cancer (PC) are key reasons for the poor prognosis of this disease.
Bingyan Liu, Shaoqiu Wu, Jun Ma, Shuo Yan, Zhengguang Xiao, Linhuang Wan, Feng Zhang, Mingyi Shang, Aiwu Mao   +8 more
doaj   +1 more source

Viscoelastic hydrogel potentiates cancer cell stemness and drug resistance through Piezo1‐dependent mechanotransduction

BMEMat, EarlyView.
The effects of matrix dynamics on cancer progression remain unclear. Herein, we fabricated a tunable dynamic hydrogel via reversible host–guest crosslinking and demonstrated that high matrix dynamics activate Piezo1 and its downstream PI3K/AKT and Wnt/β‐catenin signaling pathways, thereby enhancing cancer spheroid assembly, elevating cancer stemness ...
Yi Liu, Huiyao Deng, Hanlei Zhang, Chutian Huang, Huolun Feng, Xiayi Xu, Heemin Kang, Meiling Zhu, Liming Bian, Kunyu Zhang   +9 more
wiley   +1 more source

Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer

International Journal of Oncology, 2015
Controversial effects of thalidomide for solid malignancies have been reported. In the present study, we evaluate the effects of thalidomide for transitional cell carcinoma (TCC), the most common type of bladder cancer. Thalidomide precipitates were observed when its DMSO solution was added to the culture medium.
Yen Ta, Huang, Chuan Chu, Cheng, Ted H, Chiu, Pei Chun, Lai   +3 more
openaire   +3 more sources

Presentation_1_Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma.PDF

, 2018
Gemcitabine resistance is currently the main problem of chemotherapy for advanced pancreatic cancer patients. The resistance is thought to be caused by altered drug metabolism or reduced apoptosis of cancer cells.
Mei Huang (49698), Futao Meng (5339075), Qiang Huang (43791), Feng Shao (112229)   +3 more
core   +1 more source

Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts

Journal of Translational Medicine
Background With poor prognosis and high mortality, pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. Standard of care therapies for PDAC have included gemcitabine for the past three decades, although resistance often ...
Mariam M. Konaté, Julia Krushkal, Ming-Chung Li, Li Chen, Yuri Kotliarov, Alida Palmisano, Rini Pauly, Qian Xie, P. Mickey Williams, Lisa M. McShane, Yingdong Zhao   +10 more
doaj   +1 more source

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression

, 2018
Zhongyi Guo,1 Feng Wang,2 Yang Di,1 Lie Yao,1 Xinzhe Yu,1 Deliang Fu,3 Ji Li,3 Chen Jin1 1Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai, China; 2School of Pharmacy & Key Laboratory of Smart Drug Delivery, Fudan ...
Yao L, Li J, Guo ZY, Jin C, Wang F, Fu DL, Yu XZ, Di Y   +7 more
core  

Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050 [PDF]

Background: Antimicrobial resistance (AMR) poses an important global health challenge in the 21st century. A previous study has quantified the global and regional burden of AMR for 2019, followed with additional publications that provided more detailed ...
GBD, 2021 Antimicrobial Resistance Collaborators, GBD 2021 Antimicrobial Resistance Collaborators   +1 more
core   +1 more source